Skip to main content
Premium Trial:

Request an Annual Quote

Roche Inks $3.4 Billion Deal to Acquire Ventana

NEW YORK (GenomeWeb News) — Nearly seven months after its initial $3 billion bid to acquire Ventana Medical Systems was rebuffed by that company’s board of directors, Roche today announced that it has signed a definitive merger agreement with Ventana valued at roughly $3.4 billion.
Under terms of the agreement, Roche will acquire Ventana for $89.50 per share in cash, up from its previously rejected bid of $75 per share. In early trade on the Nasdaq, Ventana’s shares were up 4.1 percent at $88.86 per share.
Roche’s offer at $89.50 will expire at 7:00 PM EST on Feb. 7, and Ventana’s board will recommend the firm’s shareholders tender their shares to Roche.
Roche had extended its offer at $75 per share several times over the past six months, but Ventana’s board repeatedly called the offer “grossly inadequate.” As of last week, less than .2 percent of Ventana’s approximately 35 million outstanding shares had been tendered pursuant to the $75 per share offer.
The Ventana acquisition will provide Roche with a tissue-based diagnostics platform, which it currently lacks and sees as an important piece of the oncology diagnostics market.
“Our combined company will be uniquely positioned to further expand Ventana's business globally and together develop more cost-efficient, differentiated and targeted medicines,” Franz Humer, chairman and CEO of Roche, said in a statement today.
Christopher Gleeson, Ventana's president and CEO, will continue as CEO of Ventana's business following completion of the acquisition and also will become a member of the Roche Diagnostics Executive Committee. Ventana will remain based in Tucson, Ariz. and Roche expects its employees will become part of the combined company.

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.